Roivant rises as drug succeeds in two late-stage trials for eye disease
Yesterday 17:33
BUZZ-Roivant rises as drug succeeds in two late-stage trials for eye disease ** Shares of Roivant ROIV.O rise 4.35% to $36.44
** Co's drug brepocitinib meets main goals of two late-stage trials
** The pill, which is branded as Lisraya, was more effective than placebo in treating the inflammatory eye disease non-infectious uveitis (NIU)
** Adds intends to file an application for brepocitinib for the treatment of NIU in the first half of 2027
** "We believe this is a major win for brepocitinib given that NIU represents a lucrative market opportunity with especially high unmet needs," Piper Sandler says
** Lisraya is approved for dermatomyositis, a condition that causes painful skin rashes and progressive muscle weakness
** Including sessions moves, ROIV up 68% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple